Purchase of ANMI PSMA SETRILE 360 VIALS and ANMI ELUTION TOOLS GEN A

The Royal Marsden Hospital requires purchase of ANMI PSMA Setrile 360 VIALS and ANMI Elution Tools Gen A to treat prostate cancer.

ANMI PSMA Setrile 360 Vials and ANMI Elution Tools Gen A is the only viable kit for imaging of prostate cancer in UK

PMSA-11 is the most specific peptide-chelator available for diagnosis of prostate cancer.

No other available treatment as effective are available on the NHS - Ga-68 PSMA scan can be used in PET imaging. PET imaging provides greater resolution and speed of imaging and therefore diagnosis of prostate cancer.

PSMA (Prostate Specific Membrane Antigens) are over expressed on Prostate Tumours and therefore, by targeting and Imaging them with Radiopharmaceutical compounds, enables clinicians to better diagnose and manage patient's recurrent prostate cancer disease.

There is currently no Marketing Authorisation for this product.

The HBEDCC-11 kit Peptide, from ANMI, is the most widely available and popular choice at this time, that efficiently labels with Ga68 and provides high quality and accurate diagnosis of Prostate PSMA.

The Royal Marsden Radiopharmacy already operates an efficient Ga68 Generator and therefore, is capable of combining with this HBEDCC-11 peptide from ANMI.

Use of Ga-68 generator enables production of Ga-68 PSMA on-site allowing flexibility of service and negates reliance on outsourced companies for delivery radiopharmaceuticlals

Curium is the official UK Distributor of the ANMI HBEDCC-11 PSMA Kit and follows the Regulated Import Pathway approved by the MHRA for this product.

Government spending data: This supplier has received £929,535 in 549 payments (over £25k) from Guy's and St Thomas' NHS FT (2023-01-06 to 2026-02-13). View full payment history →

Tender Documents

• Awarded contract notice on Contracts Finder → — Award notice